An innovative approach for the characterization of the isoforms of a monoclonal antibody product

No abstract is available for this paper.

• Publication year

  2011

• Venue

  mAbs

• Publication date

  2011-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.4161/mabs.3.6.18090PMID 22123057PMCID PMC3242836
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New drugs in melanoma: it's a whole new world.

  2011cited by this paper
• Antibody-based therapeutics to watch in 2011

  2011cited by this paper
• Engineering host cell lines to reduce terminal sialylation of secreted antibodies

  2010cited by this paper
• Characterization of antibody charge heterogeneity resolved by preparative immobilized pH gradients.

  2010cited by this paper
• Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

  2010cited by this paper
• Metrics for antibody therapeutics development

  2010cited by this paper
• Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins.

  2009cited by this paper
• Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody.

  2009cited by this paper
• Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs.

  2008cited by this paper
• Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC

  2008cited by this paper
• Antibodies for the treatment of bacterial infections: current experience and future prospects.

  2008cited by this paper
• Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

  2008cited by this paper
• Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods.

  2008cited by this paper
• Beta-elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage.

  2007cited by this paper
• Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

  2007cited by this paper
• Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion.

  2007cited by this paper
• Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

  2006cited by this paper
• Characterization of a novel modification to monoclonal antibodies: thioether cross-link of heavy and light chains.

  2005cited by this paper
• Development and regulation of monoclonal antibody products: Challenges and opportunities

  2005cited by this paper
• Analysis of isoaspartate in a recombinant monoclonal antibody and its charge isoforms.

  2003cited by this paper
• Therapeutic antibodies for human diseases at the dawn of the twenty-first century

  2003cited by this paper
• The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity*

  2003cited by this paper
• Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine.

  2002cited by this paper
• Determination of the Origin of Charge Heterogeneity in a Murine Monoclonal Antibody

  2000cited by this paper
• Real-time isoform analysis by two-dimensional chromatography of a monoclonal antibody during bioreactor fermentations.

  1998cited by this paper
• Influence of Primatone RL supplementation on sialylation of recombinant human interferon-gamma produced by Chinese hamster ovary cell culture using serum-free media.

  1997cited by this paper
• Degradative covalent reactions important to protein stability

  1997cited by this paper
• Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research.

  1997cited by this paper
• Glycosylation of antibody molecules: structural and functional significance.

  1996cited by this paper
• N-glycans of recombinant human interferon-gamma change during batch culture of chinese hamster ovary cells.

  1995cited by this paper
• N‐glycans of recombinant human interferon‐γ change during batch culture of chinese hamster ovary cells

  1995cited by this paper
• Microheterogeneity of erythropoietin carbohydrate structure.

  1995cited by this paper
• Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture.

  1995cited by this paper
• Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody.

  1992cited by this paper
• Identification of Sites of Degradation in a Therapeutic Monoclonal Antibody by Peptide Mapping

  1992cited by this paper
• Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides.

  1991cited by this paper
• A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins.

  1990cited by this paper
• Stability of Protein Pharmaceuticals

  1989cited by this paper
• Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins.

  1989cited by this paper
• Tertiary structure is a principal determinant to protein deamidation.

  1988cited by this paper
• Cleavage at Asn-Gly bonds with hydroxylamine.

  1977cited by this paper

• Monitoring of monoclonal antibody critical quality attributes and free amino acids in CHO bioprocesses using Raman spectroscopy and DUPLEX-based PLS modeling

  2025cites this paper
• In-line buffer exchange in the coupling of Protein A chromatography with weak cation exchange chromatography for the determination of charge variants of immunoglobulin G derived from chinese hamster ovary cell cultures.

  2024cites this paper
• Why is there no biosimilar of Erbitux®?

  2023cites this paper
• Glycosylation of Therapeutic Proteins: A Critical Quality Attribute.

  2021cites this paper
• Native vs Denatured: An in Depth Investigation of Charge State and Isotope Distributions.

  2020cites this paper
• Development of a 3D-LC/MS workflow for fast, automated and effective characterization of glycosylation patterns of biotherapeutic products.

  2020cites this paper
• Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?

  2019cites this paper
• Stability-Indicating Size Exclusion Chromatography Method for the Analysis of IgG mAb-Cetuximab

  2019cites this paper
• Characterization of recombinant monoclonal antibody charge variants using WCX chromatography, icIEF and LC-MS/MS.

  2019cites this paper
• Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept

  2018cites this paper
• Development and Validation of Salt Gradient CEX Chromatography Method for Charge Variants Separation and Quantitative Analysis of the IgG mAb-Cetuximab

  2018cites this paper
• Correlating charge heterogeneity data generated by agarose gel isoelectric focusing and ion exchange chromatography methods.

  2018cites this paper
• Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.

  2017cites this paper
• Transitioning from first‐ to second‐generation biosimilars: An appraisal of regulatory and post‐marketing challenges

  2017cites this paper
• Glycans and glycan-specific IgE in clinical and molecular allergology: Sensitization, diagnostics, and clinical symptoms.

  2017cites this paper
• Comparability study of Rituximab originator and follow‐on biopharmaceutical

  2017cites this paper
• Impact of cell culture on recombinant monoclonal antibody product heterogeneity

  2016cites this paper
• Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS.

  2016cites this paper
• Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.

  2015cites this paper
• Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2011-2012.

  2015cites this paper
• Continuous precipitation of IgG from CHO cell culture supernatant in a tubular reactor.

  2015cites this paper
• Characterization of the N-terminal heterogeneities of monoclonal antibodies using in-gel charge derivatization of α-amines and LC-MS/MS.

  2015cites this paper
• Qualitative and Quantitative Characterization of Therapeutic Antibodies by Native Mass Spectrometry

  2014cites this paper
• Heterogeneity of IgGs: Role of Production, Processing, and Storage on Structure and Function

  2014cites this paper
• Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation

  2014cites this paper
• Protéines de fusion immunomodulatrices et leurs procédés de fabrication

  2014cites this paper
• Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality.

  2014cites this paper
• A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines

  2013cites this paper
• Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry.

  2013cites this paper
• Approval of the first biosimilar antibodies in Europe

  2013cites this paper
• Characterization of immunoglobulin by mass spectrometry with applications for the clinical laboratory

  2013cites this paper
• Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques

  2013cites this paper
• Clinical considerations for biosimilar antibodies

  2013cites this paper
• Characterization of therapeutic antibodies and related products.

  2013cites this paper
• Analytical characterization of biosimilar antibodies and Fc-fusion proteins

  2013cites this paper
• Marketing approval of mogamulizumab

  2012cites this paper
• Exploring an orbitrap analyzer for the characterization of intact antibodies by native mass spectrometry.

  2012cites this paper
• Etablierung eines Orbitrap‐Analysators zur Charakterisierung von intakten Antikörpern mittels nativer Massenspektrometrie

  2012cites this paper
• A triumph for glyco-engineering

  2012cites this paper